Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
复制标题
DOI：
--
复制
发表时间：
2005
影响因子：
5.4
通讯作者：
E. T. Janson
中科院分区：
文献类型：
--
作者：
E. T. Janson
生长抑素是一种具有多种生物学功能的肽激素，抑制内分泌细胞的激素分泌是其中之一。神经内分泌肿瘤通常表达生长抑素受体（SSTRs），尽管在特定肿瘤中表达的SSTRs的亚型和数量变化很大。生长抑素类似物治疗的主要目的是减少激素的产生和分泌，从而控制激素诱导的症状，而生长抑素类似物延缓肿瘤生长的能力则没有很好的文献记载。所有考虑接受生长抑素类似物治疗的患者都应进行SSTR扫描（111In-pentetreotide）以确定SSTR状态，因为其表达通常与治疗反应相关。通过这种方法，可以选择适合治疗的患者。在表达SSTR的功能性神经内分泌肿瘤患者中，超过80%的患者在生长抑素类似物治疗期间症状缓解，而非功能性肿瘤的治疗仍存在一定争议。
Somatostatin is a peptide hormone that posses several biological functions of which inhibition of hormone secretion from endocrine cells is one. Neuroendocrine tumors usually express somatostatin receptors (SSTRs), although the subtypes and number of SSTRs expressed in a certain tumor is very variable. The primary goal of somatostatin analog treatment is to decrease hormone production and secretion, resulting in control of hormone induced symptoms, while the ability of somatostatin analogs to retard tumor growth is less well documented. All patients considered for somatostatin analog treatment should undergo SSTR scintigraphy (111In-pentetreotide) to establish SSTR status, since the expression is usually correlated to therapeutic response. By this approach, it is possible to select patients suitable for treatment. Among patients with functioning neuroendocrine tumors expressing SSTR, more than 80% respond with symptomatic relief during somatostatin analog treatment, while treatment of non-functioning tumors still remains somewhat controversial.